Tocqueville Asset Management L.P. boosted its position in shares of Sanofi (NYSE:SNY) by 14.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 255,713 shares of the company’s stock after buying an additional 31,980 shares during the period. Tocqueville Asset Management L.P.’s holdings in Sanofi were worth $10,702,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Dodge & Cox raised its position in Sanofi by 7.2% in the first quarter. Dodge & Cox now owns 53,530,129 shares of the company’s stock valued at $2,149,770,000 after buying an additional 3,615,056 shares during the period. Hamlin Capital Management LLC bought a new position in Sanofi during the second quarter valued at approximately $56,725,000. Chubb Ltd. bought a new position in Sanofi during the first quarter valued at approximately $18,072,000. Bank of Montreal Can bought a new position in Sanofi during the second quarter valued at approximately $16,073,000. Finally, Aviance Capital Management LLC raised its position in Sanofi by 113.7% in the second quarter. Aviance Capital Management LLC now owns 462,941 shares of the company’s stock valued at $19,374,000 after buying an additional 246,323 shares during the period. Hedge funds and other institutional investors own 9.37% of the company’s stock.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Shares of Sanofi (NYSE:SNY) traded down 1.09% during trading on Monday, reaching $37.34. The company’s stock had a trading volume of 1,239,387 shares. The company’s 50-day moving average price is $38.65 and its 200 day moving average price is $40.40. The stock has a market capitalization of $96.11 billion, a price-to-earnings ratio of 20.84 and a beta of 0.98. Sanofi has a 1-year low of $37.20 and a 1-year high of $51.88.

Several research analysts have commented on SNY shares. Citigroup Inc. reissued a “neutral” rating on shares of Sanofi in a research report on Tuesday, June 28th. Zacks Investment Research lowered Sanofi from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. TheStreet raised Sanofi from a “hold” rating to a “buy” rating in a research report on Wednesday, July 27th. Berenberg Bank reaffirmed a “hold” rating and set a $93.00 target price on shares of Sanofi in a research report on Monday, August 15th. Finally, BNP Paribas raised Sanofi from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $60.50.

Sanofi Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

5 Day Chart for NYSE:SNY

Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.